Current Rating and Its Significance
MarketsMOJO’s 'Buy' rating for Venus Remedies Ltd indicates a positive outlook on the stock’s potential for growth and value creation. This recommendation is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. Investors should understand that a 'Buy' rating suggests the stock is expected to outperform the broader market or its sector peers over the medium term, making it a favourable addition to a diversified portfolio.
Quality Assessment
As of 29 May 2026, Venus Remedies Ltd holds an average quality grade. This reflects a stable operational foundation with consistent profitability and sound management practices. The company is net-debt free, which is a significant indicator of financial health, reducing risk related to leverage. Additionally, the firm has demonstrated healthy long-term growth, with operating profit expanding at an annualised rate of 45.72%. This robust growth trajectory underpins the company’s ability to sustain earnings and invest in future opportunities.
Valuation Perspective
The valuation grade for Venus Remedies Ltd is considered fair. The stock currently trades at a price-to-book value of 2.5, which is a premium relative to its peers’ historical averages. However, this premium is justified by the company’s strong earnings growth, with net profit increasing by 126.19% recently and a remarkable 174% rise over the past year. The price-to-earnings-to-growth (PEG) ratio stands at a low 0.1, signalling that the stock is undervalued relative to its earnings growth potential. This combination of fair valuation and strong growth metrics supports the 'Buy' rating.
Financial Trend and Performance
The financial trend for Venus Remedies Ltd is very positive. The company has reported positive results for six consecutive quarters, highlighting consistent operational momentum. Key quarterly metrics reached record highs recently, including net sales of ₹259.40 crores and PBDIT of ₹63.42 crores. Return on capital employed (ROCE) for the half-year period is strong at 19.85%, while return on equity (ROE) stands at a healthy 15.5%. These figures demonstrate efficient capital utilisation and profitability, which are critical for sustaining investor confidence and supporting future growth.
Technical Outlook
The technical grade for Venus Remedies Ltd is bullish, reflecting positive market sentiment and momentum. The stock has delivered exceptional returns over various time frames as of 29 May 2026: a 1-day gain of 5.00%, 1-week increase of 18.46%, 1-month surge of 37.53%, and an impressive 3-month rise of 90.86%. Over the past six months, the stock has appreciated by 85.48%, with a year-to-date return of 67.26%. Most notably, the stock has generated a remarkable 215.27% return over the last year. This strong price performance is supported by increasing participation from institutional investors, who have raised their stake by 0.72% in the previous quarter, now collectively holding 4% of the company. Institutional interest often signals confidence in the company’s fundamentals and growth prospects.
Implications for Investors
For investors, the 'Buy' rating on Venus Remedies Ltd suggests that the stock is well-positioned to deliver attractive returns, supported by solid fundamentals and positive market dynamics. The company’s net-debt-free status, strong profit growth, and efficient capital utilisation reduce financial risk, while the fair valuation and low PEG ratio indicate that the stock is reasonably priced relative to its growth potential. The bullish technical indicators and rising institutional interest further reinforce the stock’s appeal.
Investors should consider these factors in the context of their own risk tolerance and portfolio objectives. While the pharmaceutical and biotechnology sector can be subject to regulatory and market volatility, Venus Remedies Ltd’s consistent performance and growth metrics provide a compelling case for inclusion in a growth-oriented portfolio.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Sector and Market Context
Venus Remedies Ltd operates within the Pharmaceuticals & Biotechnology sector, a space characterised by innovation, regulatory complexity, and growth driven by healthcare demand. The company’s microcap status means it is smaller in market capitalisation compared to large-cap peers, which can offer higher growth potential but also greater volatility. The stock’s recent performance and fundamentals suggest it is outperforming many peers in the sector, supported by strong operational execution and financial discipline.
Summary of Key Metrics as of 29 May 2026
To summarise, the latest data shows:
- Net sales quarterly high of ₹259.40 crores
- PBDIT quarterly high of ₹63.42 crores
- Operating profit annual growth rate of 45.72%
- Net profit growth of 126.19% recently and 174% over the past year
- ROCE (half-year) at 19.85%
- ROE at 15.5%
- Price to Book Value of 2.5
- PEG ratio of 0.1
- Stock returns: 1Y +215.27%, YTD +67.26%, 6M +85.48%, 3M +90.86%
These figures collectively underpin the 'Buy' rating and highlight the company’s strong growth trajectory and attractive valuation.
Conclusion
Venus Remedies Ltd’s current 'Buy' rating by MarketsMOJO reflects a well-rounded assessment of its quality, valuation, financial trend, and technical outlook as of 29 May 2026. The company’s solid fundamentals, impressive earnings growth, and positive market momentum make it a compelling option for investors seeking exposure to the Pharmaceuticals & Biotechnology sector. While all investments carry risk, the data suggests that Venus Remedies Ltd is positioned favourably to deliver sustained value over the coming months and years.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
